In this issue:
Ixekizumab for patients with non-radiographic axial spondyloarthritis
Factors associated with damage accrual in patients with SLE with no clinical or serological disease activity
Hydroxychloroquine is associated with a lower risk of polyautoimmunity
Obesity reduces effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in RA
Clinical manifestations and disease burden of radiographic vs non-radiographic axial spondyloarthritis over 5 years
MRI of lesions in the sacroiliac joints for differentiation of patients with axial spondyloarthritis from control subjects with or without pelvic or buttock pain
Safety and efficacy of ICIs in patients with cancer and preexisting autoimmune disease
Disease-modifying effects of a novel cathepsin K inhibitor in OA
Irbesartan in Marfan syndrome
Comparative effectiveness of certolizumab pegol, abatacept, and biosimilar infliximab in patients with RA
Please login below to download this issue (PDF)